AIM: To investigate intraperitoneal transplantation of microencapsulated hepatic-like cells from human umbilical cord blood for treatment of hepatic failure in rats. METHODS: CD34+ cells in umbilical cord blood cells ...AIM: To investigate intraperitoneal transplantation of microencapsulated hepatic-like cells from human umbilical cord blood for treatment of hepatic failure in rats. METHODS: CD34+ cells in umbilical cord blood cells were isolated by magnetic cell sorting. In the in vitro experiment, sorted CD34+ cells were amplified and induced into hepatic-like cells by culturing with a combination of fibroblast growth factor 4 and hepatocyte growth factor. Cultures without growth factor addition served as controls. mRNA and protein levels for hepatic-like cells were analyzed by reverse transcription-polymerase chain reaction, immunohistochemistry and immunofluorescence. In the in vivo experiment, the hepatic-like cells were encapsulated and transplanted into the abdominal cavity of acute hepatic failure (AHF) rats at 48 h after D-galactosamine induction of acute hepatic failure. Transplantation with PBS and unencapsulated hepatic-like cells served as controls. The mortality rate, hepatic pathological changes and serum biochemical indexes were determined. The morphology and structure of microcapsules in the greater omentum were observed. RESULTS: Human albumin, alpha-fetoprotein and GATA-4 mRNA and albumin protein positive cells were found among cultured cells after 16 d. Albumin level in culture medium was significantly increased after culturing with growth factors in comparison with culturing without growth factor addition (P < 0.01). Compared with the unencapsulated group, the mortality rate of the encapsulated hepatic-like cell-transplanted group was significantly lower (P < 0.05). Serum biochemical parameters, alanine aminotransferase, aspartate aminotransferase and total bilirubin in the encapsulated group were significantly improvement compared with the PBS control group (P < 0.01). Pathological staining further supported these findings. At 1-2 wk post-transplantation, free microcapsules with a round clear structure and a smooth surface were observed in peritoneal lavage fluid, surviving cells inside microcapsules were found by trypan blue staining, but some fibrous tissue around microcapsules was also detected in the greater omentum of encapsulated group by hematoxylin and eosin staining. CONCLUSION: Transplantation of microencapsulated hepatic-like cells derived from umbilical cord blood cells could preliminarily alleviate the symptoms of AHF rats.展开更多
目的探讨对小儿重症肺炎患者采用纤维支气管镜肺泡灌洗方法治疗后获得的临床疗效以及安全性。方法选取2019年1月1日—2020年12月31日收治的92例小儿重症肺炎患者进行治疗研究;采用数字奇偶法分为常规组(基础治疗)和研究组(基础治疗+纤...目的探讨对小儿重症肺炎患者采用纤维支气管镜肺泡灌洗方法治疗后获得的临床疗效以及安全性。方法选取2019年1月1日—2020年12月31日收治的92例小儿重症肺炎患者进行治疗研究;采用数字奇偶法分为常规组(基础治疗)和研究组(基础治疗+纤维支气管镜肺泡灌洗治疗),各46例;比较两组患儿治疗总有效率、肺功能指标[第1秒用力呼气容积(forced expiratory volume in the first second,FEV_(1))、用力肺活量(forced vital capacity,FVC)]、动脉血气分析指标[动脉血氧分压(arterial partial pressure of oxygen,PaO_(2))、血氧饱和度(blood oxygen saturation,SaO_(2))、动脉血二氧化碳分压(arterial partial pressure of carbon dioxide,PaCO_(2))]、血清炎症因子指标[C反应蛋白(C-reactive protein,CRP)、降钙素原(procalcitonin,PCT)、白细胞计数(white blood cell count,WBC)]、并发症(剧烈咳嗽、窦性心动过速、窦性心动过缓)总发生率。结果研究组治疗总有效率(95.65%)高于常规组(76.09%),差异有统计学意义(P<0.05);研究组FEV_(1)水平、FVC水平高于常规组,差异有统计学意义(P<0.05);研究组PaO_(2)、SaO_(2)水平均高于常规组,PaCO_(2)水平低于常规组,差异有统计学意义(P<0.05);研究组CRP、PCT、WBC水平均低于常规组,差异有统计学意义(P<0.05);研究组并发症总发生率(2.17%)同常规组(4.35%)比较,差异无统计学意义(P>0.05)。结论纤维支气管镜肺泡灌洗方法有效应用后,在保证治疗安全性前提下,可促进小儿重症肺炎患者临床疗效、预后水平提升。展开更多
基金Supported by Guangdong Natural Science Foundation (9151030002000008)Shenzhen Science and Technology Plan-ning Priority Program (JH200205270412B, 200808001, 200801012)
文摘AIM: To investigate intraperitoneal transplantation of microencapsulated hepatic-like cells from human umbilical cord blood for treatment of hepatic failure in rats. METHODS: CD34+ cells in umbilical cord blood cells were isolated by magnetic cell sorting. In the in vitro experiment, sorted CD34+ cells were amplified and induced into hepatic-like cells by culturing with a combination of fibroblast growth factor 4 and hepatocyte growth factor. Cultures without growth factor addition served as controls. mRNA and protein levels for hepatic-like cells were analyzed by reverse transcription-polymerase chain reaction, immunohistochemistry and immunofluorescence. In the in vivo experiment, the hepatic-like cells were encapsulated and transplanted into the abdominal cavity of acute hepatic failure (AHF) rats at 48 h after D-galactosamine induction of acute hepatic failure. Transplantation with PBS and unencapsulated hepatic-like cells served as controls. The mortality rate, hepatic pathological changes and serum biochemical indexes were determined. The morphology and structure of microcapsules in the greater omentum were observed. RESULTS: Human albumin, alpha-fetoprotein and GATA-4 mRNA and albumin protein positive cells were found among cultured cells after 16 d. Albumin level in culture medium was significantly increased after culturing with growth factors in comparison with culturing without growth factor addition (P < 0.01). Compared with the unencapsulated group, the mortality rate of the encapsulated hepatic-like cell-transplanted group was significantly lower (P < 0.05). Serum biochemical parameters, alanine aminotransferase, aspartate aminotransferase and total bilirubin in the encapsulated group were significantly improvement compared with the PBS control group (P < 0.01). Pathological staining further supported these findings. At 1-2 wk post-transplantation, free microcapsules with a round clear structure and a smooth surface were observed in peritoneal lavage fluid, surviving cells inside microcapsules were found by trypan blue staining, but some fibrous tissue around microcapsules was also detected in the greater omentum of encapsulated group by hematoxylin and eosin staining. CONCLUSION: Transplantation of microencapsulated hepatic-like cells derived from umbilical cord blood cells could preliminarily alleviate the symptoms of AHF rats.
文摘目的探讨对小儿重症肺炎患者采用纤维支气管镜肺泡灌洗方法治疗后获得的临床疗效以及安全性。方法选取2019年1月1日—2020年12月31日收治的92例小儿重症肺炎患者进行治疗研究;采用数字奇偶法分为常规组(基础治疗)和研究组(基础治疗+纤维支气管镜肺泡灌洗治疗),各46例;比较两组患儿治疗总有效率、肺功能指标[第1秒用力呼气容积(forced expiratory volume in the first second,FEV_(1))、用力肺活量(forced vital capacity,FVC)]、动脉血气分析指标[动脉血氧分压(arterial partial pressure of oxygen,PaO_(2))、血氧饱和度(blood oxygen saturation,SaO_(2))、动脉血二氧化碳分压(arterial partial pressure of carbon dioxide,PaCO_(2))]、血清炎症因子指标[C反应蛋白(C-reactive protein,CRP)、降钙素原(procalcitonin,PCT)、白细胞计数(white blood cell count,WBC)]、并发症(剧烈咳嗽、窦性心动过速、窦性心动过缓)总发生率。结果研究组治疗总有效率(95.65%)高于常规组(76.09%),差异有统计学意义(P<0.05);研究组FEV_(1)水平、FVC水平高于常规组,差异有统计学意义(P<0.05);研究组PaO_(2)、SaO_(2)水平均高于常规组,PaCO_(2)水平低于常规组,差异有统计学意义(P<0.05);研究组CRP、PCT、WBC水平均低于常规组,差异有统计学意义(P<0.05);研究组并发症总发生率(2.17%)同常规组(4.35%)比较,差异无统计学意义(P>0.05)。结论纤维支气管镜肺泡灌洗方法有效应用后,在保证治疗安全性前提下,可促进小儿重症肺炎患者临床疗效、预后水平提升。
